quality control is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
The company was founded by Herbert Hyman (1931–2014) in September 1963, as a coffee service for offices. His wife Mona (whom he married in 1966) and he honeymooned in Sweden where they discovered quality coffee. This sparked the decision to import, roast and sell gourmet coffee in Los Angeles, opening the first Coffee Bean store in 1968 in the Los Angeles neighborhood of Brentwood. Innovations included selling whole beans and touting their country of origin and allowing customers to observe the beans being roasted and then to sample varieties before making a purchase. By the 1970s the firm had expanded to 10 stores in Southern California and had added exotic teas to the menu. In the summer of 1987 an employee brought a blender to a Westwood store where he mixed together ice, coffee extract and chocolate powder, paving the way for the company's signature Ice Blended drinks. With the invention of the Ice Blended, the chain saw a surge in popularity. The drink was a predecessor to the Starbucks Frappuccino. In 1991, when it was first planning to expand into Los Angeles, Starbucks tried to purchase the firm, but Hyman turned them down. The opening of Starbucks stores in Los Angeles unexpectedly helped Coffee Bean's business, by driving curious customers to the area. In 1996, the Hymans sold the Asian franchise rights to Singaporean brothers Victor Sassoon and Sunny Sassoon. The Sassoons quickly expanded the company in the US and internationally, opening the first outlet in Singapore in 1996, and in Malaysia the following year.
==== Combination drugs ==== Carbidopa/entacapone/levodopa (LECIGel; LECIGon; Lecigon; Trigel) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor), entacapone (catechol O-methyltransferase (COMT) inhibitor), and levodopa (dopamine precursor) [345] Levodopa/carbidopa/entacapone (ELC-200; Stalevo; Stavelo) – combination of levodopa (dopamine precursor), carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor), and entacapone (catechol O-methyltransferase (COMT) inhibitor) [346]
== Synthesis == Carbonyl sulfide was first described in 1841, but was apparently mischaracterized as a mixture of carbon dioxide and hydrogen sulfide. Carl von Than first characterized the substance in 1867. It forms when carbon monoxide reacts with molten sulfur:
Powell, one of Eddy's biographers, wrote in 1907 that Quimby's son held an almost identical copy, in Quimby's wife's handwriting, of the Quimby manuscript that Eddy had used when teaching Sally Wentworth. It was dated February 1862, eight months before Eddy met Quimby. In July 1904 the New York Times obtained a copy of the Quimby manuscript from Sally Wentworth's son, and juxtaposed passages with Science and Health to highlight the similarities. It also published Eddy's handwritten notes on Quimby's manuscript to show what the newspaper alleged was the transition from his words to hers. Quimby's manuscripts were published in 1921. Eddy's biographers continued to disagree about his influence on Eddy. Bates and Dittemore, the latter a former director of the Christian Science church, argued in 1932 that "as far as the thought is concerned, Science and Health is practically all Quimby," except for malicious animal mesmerism. Robert Peel, who also worked for the church, wrote in 1966 that Eddy may have influenced Quimby as much as he influenced her. Gardner argued in 1993 that Eddy had taken "huge chunks" from Quimby, and Gill in 1998 that there were only general similarities.
Sources: en.wikipedia.org
King Mendre, or the King of Persia (Polosi) or Anandavarma the kings of Tukhara (覩货罗, Tokharistan) had images painted in these caves for all the followers of the Buddha, by the artist and painter Mitradatta, also by Naravahanadatta, who came from a place of worship of the Niganthas, finally by Priyaratna who came from Syria (Rumakama, "Roman Empire") also with their apprentices. King Mendre and the King of Tukhara received the relics of Amitabha and went into the land of blessedness (Sukhavati). The son of the King of Tukhara called Dahuangfa (大黄发王) came to the city of Mir-li, preached the Kalachakra to all the Jaina-Niganthas and restored all the caves for the worship of Buddha. According to a recent translation by Sam van Schaik, the text should be:
Uranium is a silvery white, weakly radioactive metal. It has a Mohs hardness of 6, sufficient to scratch glass and roughly equal to that of titanium, rhodium, manganese and niobium. It is malleable, ductile, slightly paramagnetic, strongly electropositive and a poor electrical conductor. Uranium metal has a very high density of 19.1 g/cm3, denser than lead (11.3 g/cm3), but slightly less dense than tungsten and gold (19.3 g/cm3). Uranium metal reacts with almost all non-metallic elements (except noble gases) and their compounds, its reactivity increasing with temperature. Hydrochloric and nitric acids dissolve uranium, but non-oxidizing acids other than hydrochloric acid attack the element very slowly. When finely divided, it can react with cold water; in air, uranium metal becomes coated with a dark layer of uranium dioxide. Uranium in ores is extracted chemically and converted into uranium dioxide or other chemical forms usable in industry. In 1938, Otto Hahn and Fritz Strassman discovered that barium was a product of bombarding uranium-235 with neutrons, and a year later Lise Meitner and Otto Robert Frisch developed the theory of nuclear fission to explain this new phenomenon, making U-235 the first fissile isotope to be discovered. On bombardment with slow neutrons, uranium-235 most of the time splits into two smaller nuclei, releasing nuclear binding energy and more neutrons. If too many of these neutrons are absorbed by other uranium-235 nuclei, a nuclear chain reaction occurs that results in a burst of heat or (in some circumstances) an explosion.
=== Modularity === This is the ability of a system or component to operate without reference to its context. The most used standardized DNA parts are BioBrick plasmids, invented by Tom Knight in 2003. Biobricks are stored at the Registry of Standard Biological Parts in Cambridge, Massachusetts. The BioBrick standard has been used by tens of thousands of students worldwide in the international Genetically Engineered Machine (iGEM) competition. BioBrick Assembly Standard 10 promotes modularity by allowing BioBrick coding sequences to be spliced out and exchanged using restriction enzymes EcoRI or XbaI (BioBrick prefix) and SpeI and PstI (BioBrick suffix). Sequence overlap between two genetic elements (genes or coding sequences), called overlapping genes, can prevent their individual manipulation. To increase genome modularity, the practice of genome refactoring or improving "the internal structure of an existing system for future use, while simultaneously maintaining external system function" has been adopted across synthetic biology disciplines. Some notable examples of refactoring including the nitrogen fixation cluster and type III secretion system along with bacteriophages T7 and ΦX174. While DNA is most important for information storage, a large fraction of the cell's activities are carried out by proteins. Tools can send proteins to specific regions of the cell and to link different proteins together.
Joseph Berke M.D. (17 January 1939 – 11 January 2021) was an American–born psychotherapist, author of over ten books and lecturer; studied at Columbia College of Columbia University and Albert Einstein College of Medicine; moved to London where he worked with R. D. Laing when Philadelphia Association was being established; was resident at Kingsley Hall; later became an artist and writer; collaborated on a number of projects with Laing, including the Dialectics of Liberation international conference in London; co-founder of the Arbours Association in London and founder and director of Arbours Crisis Centre (1973–2010) in London. He was the author of many articles and books on psychological, social, and religious themes. J. D. Bernal (10 May 1901 – 15 September 1971) was an Irish scientist of Sephardi ancestry who pioneered the use of X-ray crystallography in molecular biology, published on the history of science, wrote popular books on science and society; was a communist activist and a member of the Communist Party of Great Britain (CPGB); his book The World, the Flesh and the Devil called "the most brilliant attempt at scientific prediction ever made" by Arthur C. Clarke. It is famous for having been the first to propose the so-called Bernal sphere, a type of space habitat intended for permanent residence. The second chapter explores radical changes to human bodies and intelligence and the third discusses the impact of these on society.
== History == In 1938, the Clinical Maternity Hospital No.3 of Yerevan was established. The current building has been operational since 1964. In 2001, the maternity hospital was transformed into the Shengavit Medical Center with a share belonging to the Yerevan municipality. In 2002, the ownership of the hospital became the property of the staff and it was reorganized into a multi-disciplinary clinical-diagnostic institution.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.